Highlights

• Medical Developments filed a CEO transition announcement alongside its September-quarter activities and Cash Flow report.

• Both market-sensitive announcements appeared on 15 October 2026, before subsequent substantial holder filings were submitted.

• The company operates across pharmaceuticals and medical and veterinary equipment, according to its listed Business profile.

• Trading Volume on 11 November remained below average despite a moderate increase in the quoted share price.

A Leadership transition and quarterly reporting form the latest corporate backdrop for Medical Developments International Limited (ASX:MVP). The healthcare business lodged two market-sensitive announcements in October, followed by Shareholder notices.

Market Activity

Medical Developments shares were higher in Wednesday’s session, with ing the stock up about 3.4% at around AUD 0.455 at roughly 2:40pm AEDT on 11 November 2026, on volume of about 70,000 shares.

Recent Developments

s two price-sensitive announcements on 15 October 2026 (AEDT): a “CEO Transition” notice and the Appendix 4C and quarterly activity report for the September 2026 quarter. The company’s annual report, notice of AGM and corporate governance statement followed on 9 October, and a change in substantial holding was lodged on 29 October.

Business Profile

The ASX describes the company as a pharmaceutical drug business plus a medical and veterinary equipment business. About 113 million shares are on issue and the 52-week range runs from roughly AUD 0.365 to AUD 0.5925. Volume today of about 70,000 shares is below the average of roughly 194,000.